The guideline development group stated that more research is needed, especially to provide more credibility to the evidence for specific patient populations, and supported the continued participation of volunteers in trials of “Remdesivir”.
As reported by Censor.NET, the World Health Organization said there is no solid evidence yet that Remdesivir improves survival or any other clinical metrics in hospitalized COVID-19 patients, regardless of the severity of the disease. Therefore, it should not be recommended for the treatment of coronavirus patients.
“The data indicate no significant effect on mortality, the need for mechanical ventilation, time to clinical improvement and other important patient outcomes”, – the WHO stressed.
On May 2, 2020, Remdesivir was approved in the United States for the emergency treatment of coronavirus disease. Even then, some doctors doubted the benefits of Remdesivir for patients with COVID-19.